Breathtec Biomedical Inc. (OTCQB: BTHCF) (CSE: BTH), in collaboration with Cannabix Technologies Inc. (OTC: BLOZF) (CSE: BLO) has announced development updates for its breathalyzer disease detection device. The new device called “V3” is based off FAIMS (field asymmetric waveform ion mobility).
The “V3” is designed to operate on its own with its own FAIMS detector, but it will also work paired with a triple-quadrupole mass spectrometer (MS) device. Breathtec said in a statement that testing has shown a direct correlation between V3 device and the MS. MS is considered to be the optimal detection.
The device has also received new modifications such as a modular design allowing for faster iterative development and a size reduction.
Chief technology officer Mike Costanzo said, "Breathtec Biomedical remains dedicated to the development of a highly sensitive breathalyzer for disease detection. With our collaboration with Cannabix and the Vancouver technical team, we can expedite the testing and analysis of biomarkers related to disease.”
The device is still in development and research. Breathtec plans to continue development based off research conducted on biomarkers found in the breath connected to diseases.
Sponsored Content Release
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.